Zimmer Features New CLS(R) Brevius(TM) Stem with Kinectiv(R) Technology at EFORT Congress

COPENHAGEN, Denmark, June 1, 2011 -

- Modular Neck Options for the Proven CLS(R) Spotorno(R) Stem Body

Zimmer Holdings, Inc. (NYSE and SIX: ZMH), a global leader in
musculoskeletal care, today introduced its CLS Brevius Stem with Kinectiv
Technology at the 12th annual European Federation of National Associations of
Orthopaedics and Traumatology (EFORT) meeting in Copenhagen, Denmark. The new
hip stem is based on the CLS Spotorno Stem, one of the most reliable implants
worldwide [1-3] with more than 25 years of clinical use. The new hip stem
writes the next chapter in CLS Spotorno Stem history with the addition of
Kinectiv Technology. This technology enables surgeons to better match
patients' individual needs with modular neck options designed for independent
intra-operative adjustments.

The CLS Spotorno Hip Stem is a pioneering system for uncemented total hip
arthroplasty characterized by excellent primary and rotational stability.
Since its introduction in the 1980s, the CLS Spotorno Stem has been used in
more than 560,000 total hip arthroplasty procedures around the world [4]. The
stem has been optimized to accommodate a variety of patients' anatomies and
to bring great intraoperative flexibility.

Intra-Operative Flexibility with Kinectiv Technology

Expanding the CLS Spotorno Stem technology through a modular neck
approach combines a proven concept with more than 25 years of clinical
success with the intra-operative flexibility of modular neck options.
Kinectiv Technology offers a wide array of head center locations allowing for
an independent, intra-operative control of leg length, offset and version for
a more accurate restoration of the patient's natural anatomy. The CLS Brevius
Stem with Kinectiv Technology is shorter than conventional stems, providing
greater bone conservation compared with the original CLS Spotorno Stem.

Documented Long-Term Reliability

The CLS Stem's capacity for osseointegration has been demonstrated in a
number of clinical studies with follow-up periods up to 20 years [2, 3, 5,
7]. The Swedish Hip Arthroplasty Registry documents a 97.5% survival rate at
16 years postoperative [1]. Consistently, Muller et al. found a stable stem
fixation in 98.8% of the operated hips 17 years after implantation [3]. All
of these studies, together with the results of other clinical investigations,
some of which encompass follow-up periods of up to 20 years [7], confirm that
revision surgery after implantation of the CLS Spotorno Hip Stem body is a
rare event - again demonstrating the excellent longevity of this implant with
long-time survival rates.

Kinectiv Technology can already look back on initial periods of
clinically proven success. The results indicate that the design of the
Kinectiv Neck Implants not only gives the flexibility surgeons need to
address a wide range of patient anatomies but also meets the stringent
strength requirements. In a 2-year follow-up multicenter study conducted on
634 patients, Duwelius et al. were not able to find any complications related
to femoral implant nor fractures of a stem or modular necks or dissociations
of the nead-neck junction [6].

For more information about the advantages of CLS Brevius stem with
Kinectiv Technology, please visit the Zimmer booth at EFORT or visit
evolution.zimmer.com.

About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs,
develops, manufactures and markets orthopaedic reconstructive, spinal and
trauma devices, dental implants, and related surgical products. Zimmer has
operations in more than 25 countries around the world and sells products in
more than 100 countries. Zimmer's 2010 sales were approximately $4.2 billion.
The Company is supported by the efforts of more than 8,000 employees
worldwide.

Zimmer Safe Harbor Statement

This press release contains forward-looking statements within the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995
based on current expectations, estimates, forecasts and projections about the
orthopaedics industry, management's beliefs and assumptions made by
management. Forward-looking statements may be identified by the use of
forward-looking terms such as "may," "will," "expects," "believes,"
"anticipates," "plans," "estimates," "projects," "assumes," "guides,"
"targets," "forecasts," and "seeks" or the negative of such terms or other
variations on such terms or comparable terminology. These statements are not
guarantees of future performance and involve risks, uncertainties and
assumptions that could cause actual outcomes and results to differ
materially. For a list and description of such risks and uncertainties, see
our periodic reports filed with the U.S. Securities and Exchange Commission.
We disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise, except as may be set forth in our periodic reports.
Readers of this document are cautioned not to place undue reliance on these
forward-looking statements, since, while we believe the assumptions on which
the forward-looking statements are based are reasonable, there can be no
assurance that these forward-looking statements will prove to be accurate.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

References

[1] www.jru.orthop.gu.se; Annual report 2008

[2] Schreiner et al. Mid-term results of the cementless CLS stem. A 7- to
11-year follow-up study. Arch Orthop Trauma Surg 2001;121:321-324

[3] Muller et al. Seventeen-year survival of the cementless CLS Spotorno
stem. Arch Orthop Trauma Surg 2010;130:269-275

[4] Zimmer data on file

[5] Schramm et al. Total hip arthroplasty using an uncemented femoral
component with taper design: outcome at 10-year follow-up. Arch Orthop Trauma
2000;120:407-412

[6] Duwelius P.J, et al: Clinical Results of a Modular Neck Hip System:
Hitting the "Bull's-Eye" More Accurately, Am J Orthop. 2010; 39 (10
suppl):2-6

[7] Aldinger P.R, et al: Uncemented Grit-Blasted Straight Tapered
Titanium Stems in Patients Younger than Fifty-five Years of Age. Fifteen to
Twenty-Year Results, J Bone Joint Surg Am. 2009;91:1432-1439

Garry R. Clark, +1-574-372-4493, garry.clark at zimmer.com, or Robert J. Marshall Jr., +1-574-371-8042, robert.marshall. at zimmer.com